And what would be your take on the same former employee telling another well known finance journalist in an interview that the DEP-Docetaxel trial would complete and results announced by end of 2018, only for it to painstakingly drag on for another 5 years?
It would be understandable if some shareholders have felt misled over the journey by some of the statements out of HQ such as this and many others.
